Objectives. To investigate the efficacy, safety, and dose-response of once-weekly oral ibandronate in the prevention of postmenopausal bone loss. Design. This was a multi-centre, placebo-controlled, double-blind, randomized, 24-month phase II/III dose-finding study. Setting. Primary care units in 14 osteoporosis centres. Subjects. A total of 630 women were stratified into four strata according to time since menopause (TSM, 1-3 vs. >3 years) and baseline bone mineral density (BMD; normal: T-score ‡1 vs. osteopenic: )2.5 £ Tscore £ 1) of the lumbar spine. Interventions. Within each stratum women were further randomized to receive once-weekly ibandronate (5, 10, or 20 mg week )1 ) or placebo for 24 months.
Introduction
The bisphosphonates represent a class of synthetic pyrophosphate analogues that have been studied extensively for their ability to prevent and treat postmenopausal osteoporosis. These compounds have a high affinity to mineralized tissues, are resistant to enzymatic degradation, and are potent inhibitors of osteoclast-mediated bone resorption [1] . However, because of their low oral availability (<1%) and gastrointestinal safety concerns [2] , daily oral bisphosphonate therapy is currently associated with stringent dosing requirements (e.g. post-dose fasting and posture requirement). Several studies, however, argue that the relative inconvenience can be easily overcome by intermittent dosing of bisphosphonates with consequent improvement in long-term compliance [3, 4] . Indeed, several signs indicate that introduction of the once-weekly dosing regimen has received a rapid and extensive acceptance amongst patients [5] .
Ibandronate, a third generation, nitrogen containing bisphosphonate currently one of the most potent members of this drug-family, is under development for the treatment and prevention of osteoporosis [6] . Clinical trials demonstrated that in postmenopausal women both oral and intravenous administration of ibandronate induces dose-dependent increases in spine and hip bone mineral density (BMD) with parallel reductions in the biochemical markers of bone turnover [7] [8] [9] . Furthermore, effective and safe treatment in osteoporotic women has been achieved by both daily and intermittent dosing of the drug [8, 9] . However, the efficacy of intermittent dosing for the prevention of postmenopausal bone loss has not been investigated yet.
Therefore, the objectives of the present phase II/III study were to investigate the efficacy, safety and dose-response of once-weekly oral ibandronate in the prevention of bone loss in postmenopausal women and to examine the optimal dose for prevention.
Materials and methods

Participants
Eleven European study centres recruited patients to the study. A total of 630 postmenopausal women (1-10 years since last menstruation) were enrolled into one of the four strata based on time since menopause (TSM) and baseline BMD at the lumbar spine (L1-L4). Early postmenopausal women (TSM 1-3 years) were stratified into Stratum A (T-score ‡1.0 SD) and Stratum B ()2.5 SD £ T-score £ )1.0 SD). Older postmenopausal women (TSM 3-10 years) were stratified into Stratum C (T-score ‡1 SD) and Stratum D ()2.5 SD £ T-score £ )1.0 SD) accordingly.
Exclusion criteria ensured that none of the study participants were osteoporotic based on baseline values of BMD and the absence of any osteoporotic spine or hip fracture in medical history. Furthermore, those with any chronic disease or medication known to influence bone or calcium metabolism were also excluded from the study. Precaution was taken not to include patients with peptic ulcer or oesophagitis in the medical history.
All women gave written consent to participation and the study was carried out according to the Helsinki II Declaration and the European Guidelines for Good Clinical Practice and in adherence with local drug regulations. Local Ethics Committees approved the study protocol.
Study design and interventions
This was a multi-centre, placebo-controlled, doubleblinded, randomized, 24-month phase II/III dosefinding study. Patients were randomized to receive once-weekly therapy with oral ibandronate 5 mg (n ¼ 159), 10 mg (n ¼ 154), or 20 mg (n ¼ 159) or placebo (n ¼ 158) for 2 years. Patients were instructed to take one tablet per week and to maintain consistency in the day of the week on which the medication was taken. They were also instructed to take the tablets with at least 100 mL (4 oz) plain water and maintain an upright position. No food or drink (with the exception of water) intake was permitted for at least 6 h prior to and for at least 30 min after study medication. The post-dose fasting period was initially 60 min but was modified to 30 min in the protocol amendment (dated 25 March 1999), 10 months after the first patient was randomized. All participants received daily calcium supplementation (500 mg), which had to be taken with evening meal.
Study outcomes
The primary end-point was the mean relative change from baseline in BMD (L1-L4) after 2-years of therapy. Secondary end-points were the absolute and relative changes in BMD in the proximal femur (total hip and subregions), and relative changes from baseline in markers of bone formation (serum osteocalcin, serum bone alkaline phosphatase) and bone resorption (serum and creatinine-corrected urinary C-telopeptide of collagen type I (CTx) markers.
Bone mineral density was measured with dual energy X-ray absorptiometry (DEXA). Patient spine and hip BMD measurements were recorded at the pre-study visit (spine only), at baseline (month 0), and at months 6, 12, 18 and 24. To assure quality, all BMD measurements, with exception of the initial screening assessment, were analysed at a centralized laboratory (Synarc Inc., Portland, OR, USA).
Blood samples and urine samples (second morning void) were collected after at least 8 h of fasting between 8 and 10 o'clock in the mornings. Samples were kept deep frozen ()20°C) until analysis. Serum osteocalcin and urine CTx were measured by enzyme immunoassays (EIAs) using the automatic analyzer ES 700 from Roche Diagnostics (Mannheim, Germany). The osteocalcin assay is a one-step, whereas the urine CTx assay (b-CrossLaps) is a twostep sandwich assay using streptavidin technology. Urine CTx was corrected for urinary creatinin excretion. Serum total alkaline phosphatase was measured by the Hitachi 912 automatic analyzer (Roche Diagnostics) based on a kinetic colorimetric test. Serum CTx was also measured by EIA using the automatic system Elecsys 2010 (Roche Diagnostics). All measurements were carried out according to the manufacturer's instructions.
Safety end-points
Adverse events, parameters of renal and liver function, and other laboratory parameters including blood cell counts and electrolyte concentrations, and change from baseline in 25-OH vitamin D were assessed. All safety laboratory measurements were performed prior to randomization (baseline) and at months 3, 6, 9, 12, 15, 18 and 24.
Statistical analysis
Data are shown as mean ± SD unless otherwise indicated. Baseline characteristics were compared with one-way anova or Kruskal-Wallis test as appropriate. Analysis of the primary and secondary efficacy end-points were based on the intentionto-treat (ITT) population. The last value carried forward (LVCF) method was used for imputation of missing efficacy parameters at month 24 except for the analysis of biochemical markers of bone turnover. For comparison of the relative changes in spine and hip BMD, an F-test was carried out. KruskalWalllis test was used to compare the relative changes in bone markers with reference to the changes in placebo. Differences were considered significant if P < 0.05.
Results
A total of 630 patients were randomized to the study. All but eight patients received at least one dose of the study medication (ITT population). Of the 539 patients completed the full 24 months of the study. Patient withdrawal was most frequently due to non-medical reasons (42.2% of all withdrawals), followed by adverse events (39.8% of all withdrawals), and lost to follow-up (10.8% of all withdrawals). Within each reason for withdrawal, the distribution was fairly even without an obvious dose-related effect on withdrawal. Of the 622 patients, 14 were excluded from the intentionto-treatment analysis as a result of the lack of follow-up BMD assessment.
Baseline demographics were balanced across the four intervention groups in terms of age, weight, height, body mass index, TSM, serum level of 25-OH vitamin D, walking activity, smoking habits, and dietary habits (Table 1) . Baseline bone characteristics as shown by Table 2 were also comparable between the intervention groups.
Changes in bone mineral density in all strata combined
Once-weekly therapy with ibandronate induced dose-dependent increases in spine BMD (Fig. 1) . Statistically significant differences compared with placebo were seen already at month 6 for both the 10 and 20 mg dose groups. Therapeutical outcomes at the end of the 24-month study period in terms of the relative changes in spine BMD from baseline are indicated in Table 3 . Both the 10 and 20 mg onceweekly doses of ibandronate induced statistically significant increases in spine BMD compared with placebo. Maximum relative response evoked by 20 mg ibandronate was 2.9%. As the relative change in spine BMD from baseline was )1.1%, the difference between responses to placebo and 20 mg ibandronate reached 4.0%.
Once-weekly ibandronate evoked similar dosedependent increases in hip BMD (Fig. 2) . The relative changes from baseline to month 24 induced by 10 and 20 mg ibandronate were statistically significant compared with the placebo group ( Table 3) . The maximum relative response evoked by 20 mg ibandronate was 2.2%. Since the placebo group lost )0.6% during the same period, differences between responses to 20 mg ibandronate or placebo was 2.7%. Changes in bone mineral density by stratum
Time since menopause 1-3 years. In early postmenopausal women belonging to the placebo groups of Stratum A and B, statistical significant decreases in spine BMD were observed at the end of the 24-month follow-up period (Table 3 ). In contrast, the groups treated with ibandronate in both the normal (Stratum A) and osteopenic (Stratum B) strata displayed improved spine BMD compared with their respective placebo groups, with exception of the 5 mg group in Stratum A ( Table 3 ). The maximum relative increases in spine BMD induced by 20 mg ibandronate were 2.0% in Stratum A and 3.0% in Stratum B, which were both statistically significant compared with responses in the respective placebo groups. Notably, in osteopenic women, not only the 20 mg but also the 10 mg once-weekly dose evoked significant increases in spine BMD (Table 3) . The efficacy of ibandronate in increasing hip BMD was different in normal and osteopenic women ( Table 2) . Osteopenic women displayed statistically significant increases in all dose groups at the end of the 24-month study period compared with placebo. The increases in the 20 mg dose group compared with placebo were significant throughout the course of the study (Fig. 2) . In contrast, in women with normal BMD, the observed increases in hip BMD did not reach statistical significance compared with that seen in the respective placebo group.
Time since menopause >3 years. Women belonging to the placebo groups of this category seemed to retain their BMD in the course of the study period ( Table  3) . The 10 and 20 mg ibandronate groups showed increases in spine BMD. The responses induced by 20 mg ibandronate reached statistical significance at month 24 in both strata (Stratum C: 2.1%, Stratum D: 3.6%) compared with the respective placebo groups. In addition, in osteopenic women, the 10 mg dose group also displayed statistically significant increases in spine BMD (Table 3) .
Once-weekly therapy with 20 mg ibandronate evoked statistically significant increases in BMD not only at the spine, but also at the hip. The relative increases in hip BMD to 20 mg ibandronate were more pronounced in the osteopenic (2.6%) group compared with the normal BMD group (2.4%). In osteopenic women, 10 mg once-weekly ibandronate also evoked statistically significant increases in hip BMD (Table 3) .
Biochemical markers of bone turnover in all strata combined Figure 3 indicates the relative changes in biochemical markers of bone turnover. Ibandronate induced dose-dependent decreases in both the resorption and formation markers. A significant suppression of serum CTx was observed in the 20 mg group beginning at month 6, whilst the concentration in the placebo group showed an increase over the 24-month study period. The decreases in creatinine-corrected urinary CTx Regarding the changes in formation markers, median values of osteocalcin decreased gradually over the first year of the therapy for all groups, including placebo, and remained essentially unchanged throughout the second year. Similarly, the bone-specific alkaline phosphatase also showed an initial decrease in median values up to month 9, but subsequently a gradual increase could be observed. Similar gradual increase was seen in the placebo group indicating that this increase is caused by an assay shift. Differences between the active treatment groups and placebo were maintained up to month 24.
Changes in biochemical markers of bone turnover by stratum Time since menopause 1-3 years. Once-weekly oral therapy with 20 mg ibandronate induced consistent, statistically significant decreases in all assessed biochemical markers independently of initial BMD (Table 4). Furthermore, the changes in creatininecorrected urinary CTx from baseline induced by 10 mg ibandronate were also statistically significant.
Biochemical markers of bone formation also showed consistent decreases in the group receiving once-weekly therapy with 20 mg ibandronate, independently of initial BMD (Table 3) . In osteopenic women, the inhibition of serum osteocalcin measured at the end of the study period was statistically significant not only in the 20 but also in the 10 mg dose group.
Time since menopause >3 years. Twenty milligram ibandronate given once-weekly induced consistent, statistically significant decreases in all bone markers independently of initial BMD (Table 3 ). Ten milligram ibandronate was also able to induce significant decreases in creatinine-corrected urinary CTx in both strata. The decreases in bone resorption were more pronounced in the osteopenic group, where the decrease in serum CTx was also statistically significant compared with the respective placebo group. In the osteopenic group, decreases in serum osteocalcin induced ibandronate reached statistical significance not only in the 20 but also in the 10 mg dose group.
Safety
A large proportion of patients in each study group took at least 75% of study medication: 89% placebo, 88.8% (5 mg), 90.1% (10 mg) and 88.7% (20 mg) patients. Overall safety results indicated that oral once-weekly therapy with ibandronate was well tolerated at the three doses investigated and the safety profile was similar to placebo with no safety concerns identified. The proportion of patients experiencing >1 adverse event that was possibly or probably related to study medication was low (7.2%). Individual adverse events observed more frequently in the active treatment groups were back pain, brochitis, sinusitis, gastroenteritis, bone fracture, cystitis, gastrointestinal pain, myalgia, cholelithiasis, and periodontal abscess. The 5 and 10 mg groups had twice the number of patients experiencing drugrelated adverse events (10.0% and 9.0%, respectively) compared with the placebo and 20 mg group (5.0% and 5.0%, respectively). Although gastrointestinal adverse events were the most frequent drugrelated events, they only occurred in 3.0, 6.0, 5.0 and 3.0% of patients receiving placebo and 5 10 and 20 mg ibandronate, respectively. Eight patients withdrew from the study because of an adverse event rated as possibly related to treatment (one dyspepsia, two abdominal pain, two nausea, one duodenal ulcer, one myalgia, one hot flashes). A total of 12.5% of participants experienced a serious adverse event, but none of these events was assessed as related to the study drug (mainly cardiovascular events). Six of these patients withdrew from the study as a result of a serious adverse event not related to study medication (three lung cancer, one breast cancer, one deep thrombophlebitis, one bone fracture). There were no clinically significant changes from baseline values in any of the tested safety laboratory parameters.
Discussion
This is the first study that documents the efficacy and safety of once-weekly oral ibandronate for the prevention of postmenopausal bone loss. The main finding was that once-weekly dosing of 20 mg oral ibandronate provides an effective and safe therapy for the prevention of postmenopausal bone loss from both the spine and the hip in the early and in the later phases of the menopause.
A previous study demonstrated that an oral daily dosing of 2.5 mg ibandronate evokes maximum responses in postmenopausal women in terms of increases in spine and hip BMD [8] . Dosing convenience is a key element in the effective management of any chronic disease, and is particularly important in the long-term management of osteoporosis. Less frequent dosing with any medication is expected to enhance compliance, thereby maximizing the effectiveness of therapy. Therefore, there is an ongoing search for more convenient dosing regimens that at the same time can provide similar efficacy to that provided by the daily dosing.
Bisphosphonates are known to have a very strong affinity to calcified tissues [10] . Because their halflife of residence on bone surfaces is at least several weeks, it is reasonable to assume that the overall efficacy of the therapy is a function of the dose loaded over a period of time rather than the frequency of dosing [11] . In support of this notion, several animal studies and clinical trials demonstrated comparable efficacy of intermittent and daily dosing of ibandronate [12, 13] . These observations provided rational for the clinical testing of onceweekly oral ibandronate therapy.
Whilst the efficacy of intermittent ibandronate treatment in osteoporotic women was well documented [12, 13] , the efficacy of this dosing regimen has not been demonstrated in early postmenopausal women who are particularly at risk of rapid bone loss. Results of the present study indicated that 24-month therapy with oral ibandronate 10 or 20 mg once-weekly prevented accelerated bone loss and induced dose-dependent increases in BMD at both the lumbar spine and the hip compared with the placebo group. Therapeutic outcomes were comparable with those achieved with 2.5 mg daily dosing [8] . Although there can be several potential limitations when comparing results from different clinical trials, it is notable that the effect of once-weekly therapy with 20 mg ibandronate on spine and hip BMD is quite comparable with the effects seen with daily oral therapy with 5 mg alendronate already approved for the prevention of postmenopausal osteoporosis [14] .
Outcome in terms of the relative increases in spine BMD were more pronounced in osteopenic women in the later compared with earlier phase of the menopause. However, as expected the rate of bone loss was significantly higher in the placebo group of patients in the early years of the menopause. Therefore, when compared with the respective placebo groups the overall benefits were greatest in early postmenopausal women. Thus, these results suggest that once-weekly ibandronate therapy can not only counteract this rapid bone loss but can also induce significant increases in BMD in women who are at an increased risk for rapid bone loss.
The efficacy of ibandronate was higher in osteopenic women compared with women with normal initial BMD. This finding again illustrates that the highest efficacy of ibandronate is seen in those who may be most in the greatest need for preventive therapy. These observations could be explained by the fact that bisphosphonates bind preferentially to bone tissue of high turnover rate [15] .
Overall safety results indicated that once-weekly therapy with oral ibandronate was well tolerated and no safety concerns were identified. Once-weekly ibandronate therapy was not associated with an increased risk of adverse effects affecting the upper gastrointestinal tract. Furthermore, as indicated by a previous study intermittent administration of larger doses does not increase the incidence of adverse events and displays comparable tolerability and safety with the daily dosing [16] . Therefore, intermittent dosing regimen can be reasonably expected to increase dosing convenience and better long-term compliance amongst patients.
In summary, the present study demonstrated that once-weekly dosing of 20 mg ibandronate is safe and efficacious in the prevention of bone loss in postmenopausal women independently of age and bone mass at the start of the therapy.
